Announcements Trials
Browse Landscape

Status

Active not recruiting 11Recruiting 4Completed 2Withdrawn 1Terminated 1Enrolling by invitation 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Conditions

Advanced Cancers and FGFR Genetic Alterations 1

Interventions

tucatinib 1talquetamab 1niraparib 1futibatinib 1erdafitinib 1cemiplimab 1amivantamab 1adagrasib 1Trastuzumab 1TIC10 compound 1Prednisone 1Prednisolone 1Capecitabine 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × erdafitinib × 1 year × Clear all
NCT03825484 2025-06-13

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Janssen Scientific Affairs, LLC

Approved for marketing

Advanced Cancers and FGFR Genetic Alterations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡